Search results
Results from the WOW.Com Content Network
(Reuters) -A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies ...
This case was later overturned as the drug was found to be effective for insomnia and fibromyalgia. In 2012, the Second Circuit Court of Appeals further expanded First Amendment commercial speech protection in the realm of pharmaceutical marketing in United States v. Caronia. The court overturned a pharmaceutical sales representative’s ...
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
Sorrell v. IMS Health Inc., 564 U.S. 552 (2011), [1] is a United States Supreme Court case in which the Court held that a Vermont statute that restricted the sale, disclosure, and use of records that revealed the prescribing practices of individual doctors violated the First Amendment.
On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation ...
Novo Nordisk president and CEO Lars Fruergaard Jorgensen prepares to testify before the Senate Health, Education, Labor, and Pensions Committee on Capitol Hill on Sept. 24, 2024, in Washington, D ...
Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. [ 2 ] [ 3 ] PhRMA is headquartered in Washington, D.C. [ 1 ] The organization has lobbied fiercely against allowing Medicare to negotiate drug prices for Medicare recipients, [ 4 ] and filed lawsuits against the drug price provisions in the Inflation Reduction Act . [ 5 ]
In 2013, the American Medical Association offered physicians training to understand the Sunshine Act. [3] A recent 2024 analysis suggests nearly 60% of experts who reviewed manuscripts for four major medical journals received at least one payment from the industry over a recent three-year period, with a total exceeding $1 billion. [4]